Bicycle Therapeutics Limited Stock Price, News & Analysis

Bicycle Therapeutics (NASDAQ: BCYC) announced the presentation of preclinical data for its novel tumor-targeted immune cell agonists BT7480 and BT7455 at the Society for Immunotherapy of Cancer's 36th Annual Meeting from November 10-14, 2021. The preclinical results support the initiation of a Phase I/II trial for BT7480, indicating potential anti-tumor responses in syngeneic mouse models. The data also formed the basis for a pharmacokinetic/pharmacodynamic modeling framework to optimize dosing schedules. These developments position Bicycle Therapeutics favorably in the competitive biotechnology landscape.

Bicycle Therapeutics (NASDAQ: BCYC) reported interim Phase I results for its BT5528 and BT8009 clinical trials, indicating preliminary anti-tumor activity. Cash reserves were $259.5 million as of September 30, 2021, boosted by recent financing activities. The firm also dosed the first patient in the BT7480 Phase I/II trial, targeting advanced solid tumors. Genentech expanded its collaboration with Bicycle, triggering a $10 million payment. The company experienced an increased net loss of $14.7 million, reflecting higher R&D and administrative expenses.

Bicycle Therapeutics (NASDAQ: BCYC) announced the first patient has been dosed in a Phase I/II trial for BT7480, a novel tumor-targeted immune cell agonist targeting Nectin-4, which aims to enhance anti-tumor immunity. This marks Bicycle's first entry into immuno-oncology and its fourth product candidate in clinical development within four years. The trial will primarily assess the safety and tolerability of BT7480, which has shown encouraging preclinical results. Future trials may include combinations with nivolumab.

Bicycle Therapeutics (NASDAQ: BCYC) announced a publication in the Journal for ImmunoTherapy of Cancer featuring preclinical data on BT7480, a tumor-targeted immune cell agonist. This innovative therapy targets Nectin-4 and activates CD137 selectively in tumor environments, enhancing anti-tumor immunity with intermittent use. The findings reveal BT7480’s capability to rapidly alter the tumor immune microenvironment, leading to complete regressions in mouse models. Bicycle aims to commence a Phase I/II clinical trial by year's end, furthering its commitment to cancer treatment innovation.

bit.bio has appointed three new directors to its board, aiming to leverage their expertise to enhance its synthetic biology cell programming technology. Dr. Hermann Hauser becomes chair of the board, bringing extensive experience from founding Arm Ltd and Solexa. Sir Gregory Winter, a Nobel prize-winning scientist, joins to bolster therapeutic applications using human cells. Alan S. Roemer, an accomplished biotechnology entrepreneur, will support capital markets and operational growth strategies. Collectively, these leaders are expected to drive bit.bio's mission in transforming healthcare.

Bicycle Therapeutics (NASDAQ: BCYC) announced that Genentech has exercised an option to expand their collaboration by initiating a new program under their 2020 agreement. This expansion will allow both companies to develop novel Bicycle-based immuno-oncology therapies and triggers a $10 million payment to Bicycle. The ongoing collaboration focuses on discovering and pre-clinically developing innovative immunotherapies targeting multiple cancer types. CEO Kevin Lee expressed optimism about the partnership's potential to deliver new cancer treatments.

Bicycle Therapeutics plc (Nasdaq: BCYC) has successfully closed its public offering of 3,726,852 American Depositary Shares (ADSs) as of October 15, 2021. The offering generated $201.3 million in gross proceeds, with additional shares sold due to underwriters' options. Goldman Sachs, Morgan Stanley, and SVB Leerink served as book-running managers. The ADSs were offered under an effective shelf registration statement and available via a prospectus supplement. This offering positions Bicycle Therapeutics for future growth opportunities.

Bicycle Therapeutics plc (Nasdaq: BCYC) has priced a public offering of 3,240,741 American Depositary Shares (ADSs) at $54.00 each, aiming for gross proceeds of $175.0 million. The underwriters have a 30-day option to purchase an additional 486,111 ADSs. Proceeds will be utilized for advancing its product pipeline and for research and development. The offering is set to close on or around October 15, 2021, pending customary conditions. Goldman Sachs, Morgan Stanley, and SVB Leerink are managing the offering.

Bicycle Therapeutics plc (Nasdaq: BCYC) has launched an underwritten public offering of $125 million in American Depositary Shares (ADSs), with an option for underwriters to purchase an additional $18.75 million. The funds will support the advancement of Bicycle's product pipeline and general corporate purposes. The offering is subject to market conditions and may not be completed as planned. Major financial institutions managing the offering include Goldman Sachs, Morgan Stanley, and SVB Leerink.